About

Myosotis Investments B.V. 

Myosotis Investments B.V. is founded in 2024. It focuses on catalyzing advancements in life sciences, in particular molecular diagnostics by investing in companies that are reshaping healthcare. The firm’s portfolio includes 1) Antwerp, Belgium based company IDEVAX B.V., which is pioneering innovative intradermal delivery methods with its patented VAX-ID device to improve vaccine and therapeutic applications, 2 Welsh, UK based company Kairos Biotech Ltd., a developer of next-generation small-molecule immunotherapies aimed at enhancing transplant success and accessibility and 3) Tzu Cancer Therapeutics B.V. based on Amsterdam Science Park that was founded in July 2024 and who aims to develop personalized therapies based on the molecular analysis of Circulating Tumor Cells (CTCs).

Myosotis Investments is committed to supporting transformative technologies that address complex medical needs and drive long-term healthcare progress.

The Team 

Wietse Mulder, PhD

Wietse Mulder, PhD

Managing Partner

 

Janeska de Jonge, PhD

Janeska de Jonge, PhD

Business Development Associate

Myosotis Investments B.V. 

KVK: 94176795
RSIN: 866665547

Contact

Karpervijver 17, 3703 CJ Zeist, The Netherlands
info@myosotisinvestments.com

Follow us